Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661993 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL3365775 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| Hydrochloric Acid SCHEMBL3641313 | 0.98 | BLM (0.46) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL931564 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL7697296 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL10382831 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL1952053 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL22834112 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL21611683 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM | |
| SCHEMBL7342998 | 0.98 | PAOX (0.50) | CYP1A2PAOXCYP2D6NFKB1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0400290-A1 | 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | claimed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | claimed |
| CN-122080118-A | VH032 modified phthalocyanine and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | TRANSLATE BIO, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250325711-A1 | COVALENT FLUORESCENT PROBES FOR CANNABINOID RECEPTOR 2 | HOFFMANN-LA ROCHE INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4598582-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| EP-4577529-A2 | COVALENT FLUORESCENT PROBES FOR CANNABINOID RECEPTOR 2 | F. Hoffmann-La Roche AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| CN-119859120-A | Preparation and application of novel ligand and derivative of E3 ligase FEM1B | 重庆医科大学 | 2025-04-22 | — | — | CN | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0236734-A2 | 5-Amino-4-hydroxyvaleryl derivatives substituted by s-containing groups | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | CYP1A2 4043/4885PAOX 3112/4885CYP2D6 3400/4885 |
| US-20250325711-A1 | COVALENT FLUORESCENT PROBES FOR CANNABINOID RECEPTOR 2 | CNR2, CNR1, QRFPR | CYP1A2 340/4885PAOX 1373/4885CYP2D6 850/4885 |
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | SGMS2, SPTLC2, SGMS1 | CYP1A2 3267/4885PAOX 437/4885CYP2D6 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.